Anti-KIF19 monoclonal antibody

Pre-made anti-KIF19 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to KIF19/KIF19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2561-Ab-1/ GM-Tg-hg-IP2561-Ab-2Anti-Human KIF19 monoclonal antibodyHuman
GM-Tg-rg-IP2561-Ab-1/ GM-Tg-rg-IP2561-Ab-2Anti-Rat KIF19 monoclonal antibodyRat
GM-Tg-mg-IP2561-Ab-1/ GM-Tg-mg-IP2561-Ab-2Anti-Mouse KIF19 monoclonal antibodyMouse
GM-Tg-cynog-IP2561-Ab-1/ GM-Tg-cynog-IP2561-Ab-2Anti-Cynomolgus/ Rhesus macaque KIF19 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2561-Ab-1/ GM-Tg-felg-IP2561-Ab-2Anti-Feline KIF19 monoclonal antibodyFeline
GM-Tg-cang-IP2561-Ab-1/ GM-Tg-cang-IP2561-Ab-2Anti-Canine KIF19 monoclonal antibodyCanine
GM-Tg-bovg-IP2561-Ab-1/ GM-Tg-bovg-IP2561-Ab-2Anti-Bovine KIF19 monoclonal antibodyBovine
GM-Tg-equg-IP2561-Ab-1/ GM-Tg-equg-IP2561-Ab-2Anti-Equine KIF19 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2561-Ab-1/ GM-Tg-hg-IP2561-Ab-2; GM-Tg-rg-IP2561-Ab-1/ GM-Tg-rg-IP2561-Ab-2;
GM-Tg-mg-IP2561-Ab-1/ GM-Tg-mg-IP2561-Ab-2; GM-Tg-cynog-IP2561-Ab-1/ GM-Tg-cynog-IP2561-Ab-2;
GM-Tg-felg-IP2561-Ab-1/ GM-Tg-felg-IP2561-Ab-2; GM-Tg-cang-IP2561-Ab-1/ GM-Tg-cang-IP2561-Ab-2;
GM-Tg-bovg-IP2561-Ab-1/ GM-Tg-bovg-IP2561-Ab-2; GM-Tg-equg-IP2561-Ab-1/ GM-Tg-equg-IP2561-Ab-2
Products NameAnti-KIF19 monoclonal antibody
Formatmab
Target NameKIF19
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-KIF19 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2561-Ag-1Recombinant multi-species KIF19/ KIF19A protein


    Target information

    Target IDGM-IP2561
    Target NameKIF19
    Gene ID124602,286942,303659,697090,483285,101087950,538109,100060836
    Gene Symbol and SynonymsKIF19,KIF19A,RGD1559936
    Uniprot AccessionQ2TAC6
    Uniprot Entry NameKIF19_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000196169
    Target ClassificationN/A

    The target: KIF19, gene name: KIF19, also named as KIF19A. Predicted to enable microtubule binding activity and plus-end-directed microtubule motor activity. Predicted to be involved in axonemal microtubule depolymerization; microtubule-based movement; and plus-end specific microtubule depolymerization. Predicted to be located in cilium. Predicted to be part of kinesin complex. Predicted to be active in microtubule. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.